secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0000950170-23-004474
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q4 net product sales $24.4M; Auvelity launch nets $5.2M; Sunosi EU license $66M upfront
--------------------------------------------------------------------------------

- Q4 2022 net product sales $24.4M (Auvelity $5.2M, Sunosi $19.2M); full-year net sales $50.0M.
- Q4 net loss $61.2M ($1.41/share) vs $34.0M loss in Q4 2021; full-year loss $187.1M ($4.60/share).
- Sunosi EU license to Pharmanovia: $66M upfront, up to $101M milestones, mid-twenties royalty on net sales.
- Pro forma cash >$300M after $66M upfront and $55M tranche from amended Hercules loan facility.
- Pipeline: AXS-12 narcolepsy Phase 3 topline expected 1H 2023; AXS-07 migraine NDA resubmission 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023004474/0000950170-23-004474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023004474/axsm-20230227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer